Itulazax (Betula Verrucosa (108))

Betula verrucosa extract contains the primary birch pollen allergens. When administered sublingually, the extract is taken up by oral mucosal immune cells, which promotes the development of regulatory T‑cells and allergen‑specific IgG4 antibodies while suppressing IgE production. This immune shift reduces mast‑cell activation and alleviates allergic symptoms.

The dosing regimen for Itulazax is individualized and determined by the prescribing clinician based on the patient’s age, severity of allergy, and response to therapy. The prescriber will establish the initial dose, titration schedule, and maintenance dose according to current clinical guidelines and the product’s prescribing information.

Safety data for Itulazax in pregnancy and lactation are limited, and the product is not classified in a specific pregnancy category. Healthcare providers should evaluate the potential benefits against any possible risks before prescribing to pregnant or nursing women, and discuss alternative management options when appropriate.

To order Itulazax, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Itulazax is a sublingual immunotherapy (SLIT) product, whereas many alternative birch allergen therapies are administered via subcutaneous injection (SCIT). SLIT offers the convenience of at‑home dosing and avoids frequent clinic visits, but both approaches aim to induce long‑term tolerance. Clinical choice depends on patient preference, adherence potential, and physician assessment of efficacy and safety.

Itulazax should be stored below 25 °C in its original packaging. Protect the product from moisture, direct sunlight, and extreme temperature fluctuations. Do not freeze the preparation. Keep the container tightly closed when not in use and keep it out of reach of children.

Itulazax is administered as a sublingual preparation. The patient places the prescribed dose under the tongue, holds it there for the recommended time (usually 1–2 minutes), and then swallows. No water or food should be taken for at least 15 minutes after dosing to ensure optimal absorption.

The most serious risks include systemic allergic reactions such as anaphylaxis, angioedema affecting the lips, tongue or airway, and severe asthma exacerbations. Patients should be observed after the first few doses and instructed to seek immediate medical attention if they experience any signs of a severe reaction.

Itulazax is contraindicated in individuals with a known hypersensitivity to Betula verrucosa extract or any excipients in the formulation. It should also be avoided in patients with uncontrolled asthma, those receiving beta‑blockers for cardiovascular conditions, and persons with a history of severe systemic reactions to allergen immunotherapy.